Seres Therapeutics Inc Stock
€0.72
Your prediction
Seres Therapeutics Inc Stock
Pros and Cons of Seres Therapeutics Inc in the next few years
Pros
Cons
Performance of Seres Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Seres Therapeutics Inc | 6.900% | -2.041% | -32.710% | -85.940% | -45.038% | -95.556% | - |
Salarius Pharmaceuticals Inc. | 2.420% | -18.824% | -22.617% | -76.389% | -25.405% | -98.665% | -99.992% |
Ardelyx Inc. | -1.160% | -6.371% | -22.654% | 73.980% | 16.955% | 25.791% | - |
Evolus Inc | -0.770% | 2.362% | -2.985% | 66.667% | 39.037% | 31.287% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Overall, Seres, a company operating in the biotechnology and medical research industry, demonstrates mixed financials. While some aspects of the company's financial health appear promising, other elements suggest a need for improvement. In order to fully comprehend the financial standing of Seres, it is crucial to dive deeper into the details and evaluate the merits and demerits associated with the company's financial performance.
Strong Cash Position: Seres boasts a robust cash balance, with $163,030,000 reported on its 2022-12-31 balance sheet. This substantial cash position grants the company some degree of financial stability and flexibility, which is especially critical in the biotechnology and medical research sector, where the need to fund research and development initiatives is ongoing.
Increasing Revenue: An examination of Seres' income statements reveals a trend of increasing revenue. This indicates a potential for growth, which is a positive sign for investors.